One year on, Capri­cor's stem cell ther­a­py ap­pears to help DMD pa­tients in small study, but in­vestors balk at the da­ta

Re­peat­ed set­backs aside, lit­tle Capri­cor has sug­gest­ed it has gen­er­at­ed some long-term da­ta to sup­port its pur­suit to gar­ner ap­proval for its stem cell ther­a­py for Duchenne mus­cu­lar dy­s­tro­phy, al­though some of the da­ta ap­peared to un­der­whelmed in­vestors.

The da­ta from the small, place­bo-con­trolled mid-stage study, HOPE-2, tracked the ef­fects of the com­pa­ny’s stem cell ther­a­py CAP-1002, which is de­signed to tem­per the in­flam­ma­tion as­so­ci­at­ed with DMD, in 8 boys and young men who are in ad­vanced stages of DMD. The re­main­ing 12 en­rolled pa­tients re­ceived the place­bo.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER